Vitamin K2 or menaquinone has nine related compounds, generally subdivided into the short-chain menaquinones (with MK-4 as the most important member) and the long-chain menaquinones, of which MK-7, MK-8 and MK-9 are nutritionally the most recognized.
Vitamin K2, the main storage form in animals, has several subtypes, which differ in isoprenoid chain length. These vitamin K2 homologues are called menaquinones, and are characterized by the number of isoprenoid residues in their side chains. Menaquinones are abbreviated MK-n, where M stands for menaquinone, the K stands for vitamin K, and the n represents the number of isoprenoid side chain residues. For example, menaquinone-4 (abbreviated MK-4) has four isoprene residues in its side chain. Menaquinone-4 (also known as menatetrenone from its four isoprene residues) is the most common type of vitamin K2 in animal products since MK-4 is normally synthesized from vitamin K1 in certain animal tissues (arterial walls, pancreas, and testes) by replacement of the phytyl tail with an unsaturated geranylgeranyl tail containing four isoprene units, thus yielding menaquinone-4. This homolog of vitamin K2 may have enzyme functions distinct from those of vitamin K1.
Menaquinone-7 and other long-chain menaquinones are different from MK-4 in that they are not produced by human tissue. MK-7 may be converted from phylloquinone (K1) in the colon by Escherichia coli bacteria. However, these menaquinones synthesized by bacteria in the gut appear to contribute minimally to overall vitamin K status. MK-4 and MK-7 are both found in the United States in dietary supplements for bone health.
The U.S. Food and Drug Administration (FDA) has not approved any form of vitamin K for the prevention or treatment of osteoporosis. MK-4 (45 mg daily) has been approved by the Ministry of Health in Japan since 1995 for the prevention and treatment of osteoporosis.
All K vitamins are similar in structure: they share a “quinone” ring, but differ in the length and degree of saturation of the carbon tail and the number of repeating isopreneunits in the “side chain”. The number of repeating units is indicated in the name of the particular menaquinone (e.g., MK-4 means that four isoprene units are repeated in the carbon tail). The chain length influences lipid solubility and thus transport to different target tissues.
Carboxylation of these vitamin K-dependent Gla-proteins, besides being essential for the function of the protein, is also an important vitamin recovery mechanism since it serves as a recycling pathway to recover vitamin K from its epoxide metabolite (KO) for reuse in carboxylation.
Several human Gla-containing proteins synthesized in several different types of tissues have been discovered:
- Coagulation factors (II, VII, IX, X), as well as anticoagulation proteins (C, S, Z). These Gla-proteins are synthesized in the liver and play an important role in blood homeostasis.
- Osteocalcin. This non-collagenous protein is secreted by osteoblasts and plays an essential role in the formation of mineral in bone.
- Matrix gla protein (MGP). This calcification inhibitory protein is found in numerous body tissues, but its role is most pronounced in cartilage and in arterial vessel walls.
- Growth arrest-specific protein 6 (GAS6). GAS6 is secreted by leucocytes and endothelial cells in response to injury and helps in cell survival, proliferation, migration, and adhesion.
- Proline-rich Gla-proteins (PRGP), transmembrane Gla-proteins (TMG), Gla-rich protein (GRP) and periostin; whose precise functions are still unexplored.
Vitamin K2 has only begun[when?] to be studied, and the few studies on humans suffer from a small sample size or no reproduced results by an independent team. Reports from northern Japan correlate vitamin K consumption with improved bone health. The possible health benefits suggested for further investigation relate to bone strength and arterial health (reducing calcification or even decalcifying, with a possible reduction in blood pressure).[according to whom?]
Vitamin K is absorbed along with dietary fat from the small intestine and transported by chylomicrons in the circulation. Most of vitamin K1 is carried by triacylglycerol-rich lipoproteins (TRL) and rapidly cleared by the liver; only a small amount is released into the circulation and carried by LDL and HDL. MK-4 is carried by the same lipoproteins (TRL, LDL, and HDL) and cleared fast as well. The long-chain menaquinones are absorbed in the same way as vitamin K1 and MK-4, but are efficiently redistributed by the liver in predominantly LDL (VLDL). Since LDL has a long half life in the circulation, these menaquinones can circulate for extended times resulting in higher bioavailability for extra-hepatic tissues as compared to vitamin K1 and MK-4. Accumulation of vitamin K in extra-hepatic tissues has direct relevance to vitamin K functions not related to hemostasis.
The European Food Safety Authority (EU) and the US Institute of Medicine, on reviewing existing evidence, have decided there is insufficient evidence to publish a dietary reference value for vitamin K or for K2. They have, however, published an adequate intake (AI) for vitamin K, but no value specifically for K2. Evidence suggests K2 is converted from dietary K1, and thus no dietary intake of K2 may be needed.
Parts of the scientific literature, dating back to 1998, suggest that the AI values are based only on the hepatic requirements (i.e. related to the liver). This hypothesis is supported by the fact that the majority of the Western population exhibits a substantial fraction of undercarboxylated extra-hepatic proteins. Thus, complete activation of coagulation factors is satisfied, but there does not seem to be enough vitamin K2 for the carboxylation of osteocalcin in bone and MGP in the vascular system.
There is no known toxicity associated with high doses of menaquinones (vitamin K2). Unlike the other fat-soluble vitamins, vitamin K is not stored in any significant quantity in the liver; therefore the toxic level is not a described problem. All data available as of 2017 demonstrate that vitamin K has no adverse effects in healthy subjects. The recommendations for the daily intake of vitamin K, as issued recently by the US Institute of Medicine, also acknowledge the wide safety margin of vitamin K: “A search of the literature revealed no evidence of toxicity associated with the intake of either K1 or K2“. Animal models involving rats, if generalisable to humans, show that MK-7 is well-tolerated.
Apart from animal livers, the richest dietary source of menaquinones are fermented foods (from bacteria, not moulds or yeasts); sources include cheeses consumed in Western diets (e.g., containing MK-8 and MK-9) and fermented soybean products (e.g., in traditional nattō consumed in Japan, containing MK-7).
MK-4 is synthesized by animal tissues and is found in meat, eggs, and dairy products. Cheeses have been found to contain MK-8 at 10–20 μg per 100 g and MK-9 at 35–55 μg per 100 g. In one report, no substantial differences in MK-4 levels were observed between wild game, free-range animals, and factory farm animals.
In addition to its animal origins, menaquinones are synthesized by bacteria during fermentation and so, as stated, are found in most fermented cheese and soybean products.[non-primary source needed] As of 2001, the richest known source of natural K2 was natto fermented using the natto strain of Bacillus subtilis, which is reportedly a good source of long-chain MK-7. In nattō, MK-4 is absent as a form of vitamin K, and in cheeses it is present among the vitamins K only in low proportions.[relevant? ][better source needed] As of this date,[when?] it is unknown whether B. subtilis will produce K2 using other legumes (e.g., chickpeas, or lentils).
Food frequency questionnaire-derived estimates of relative intakes of Vitamins K in one northern European country suggest that for that population, about 90% of total vitamin K intakes are provided by K1, about 7.5% by MK-5 through MK-9 and about 2.5% by MK-4; the intense smell and strong taste of Natto appear to make this soya food a less attractive source of K2 for Western tastes.
With regard to utilisation, reports suggest that Vitamin K2 is preferred by the extrahepatic tissues (bone, cartilage, vasculature), which may be produced as MK-4 by the animal from K1, or it may be of bacterial origin (from MK-7, MK-9, and other MKs). Discussion is ongoing[clarification needed] as to what extent K2 produced by human intestinal bacteria contributes to daily vitamin K2 needs.
Supplement companies sell nattō extract reportedly standardized with regard to for K2 content, in capsule form.
|Food||Vitamin K2 (μg per 100 g)||Proportion of compounds|
|Nattō, cooked||1,034.0||0% MK-4, 1% MK-5, 1% MK-6, 90% MK-7, 8% MK-8|
|Goose liver pâté||369.0||100% MK-4|
|Australian emu oil||360[verification needed]||100% MK-4[verification needed]|
|Hard cheeses||76.3||6% MK-4, 2% MK-5, 1% MK-6, 2% MK-7, 22% MK-8, 67% MK-9|
|Soft cheeses||56.5||6.5% MK-4, 0.5% MK-5, 1% MK-6, 2% MK-7, 20% MK-8, 70% MK-9|
|Egg yolk (Netherlands)||32.1||98% MK-4, 2% MK-6|
|Goose leg||31.0||100% MK-4|
|Grass-fed ghee and butter oil||19.6–43.1
|Curd cheeses||24.8||2.6% MK-4, 0.4% MK-5, 1% MK-6, 1% MK-7, 20% MK-8, 75% MK-9|
|Egg yolk (U.S.)||15.5||100% MK-4|
|Chicken liver (raw)||14.1||100% MK-4|
|Chicken liver (pan-fried)||12.6||100% MK-4|
|Cheddar cheese (U.S.)||10.2||6% MK-4, 94% other MK|
|Meat franks||9.8||100% MK-4|
|Chicken breast||8.9||100% MK-4|
|Chicken leg||8.5||100% MK-4|
|Ground beef (medium fat)||8.1||100% MK-4|
|Luncheon meat||7.7||100% MK-4|
|Chicken liver (braised)||6.7||100% MK-4|
|Minced meat||6.7||100% MK-4|
|Calf’s liver (pan-fried)||6.0||100% MK-4|
|Hot dog||5.7||100% MK-4|
|Whipping cream||5.4||100% MK-4|
|Sauerkraut||4.8||8% MK-4, 17% MK-5, 31% MK-6, 4% MK-7, 17% MK-8, 23% MK-9|
|Pork steak||3.7||57% MK-4, 13% MK-7, 30% MK-8|
|Duck breast||3.6||100% MK-4|
|Buttermilk||2.5||8% MK-4, 4% MK-5, 4% MK-6, 4% MK-7, 24% MK-8, 56% MK-9|
|Plaice||2.2||9% MK-4, 14% MK-6, 4% MK-7, 73% MK-8|
|Eel||2.2||77% MK-4, 5% MK-6, 18% MK-7|
|Fermented cod liver oil||1.8||69% MK-4, 18% MK-6, 6% MK-8, 7% MK-9|
|Buckwheat bread||1.1||100% MK-7|
|Whole milk yogurt||0.9||67% MK-4, 11% MK-5, 22% MK-8|
|Whole milk||0.9||89% MK-4, 11% MK-5|
|Egg white||0.9||100% MK-4|
|Venison back||0.7||100% MK-4|
|Cow’s liver (pan-fried)||0.4||100% MK-4|
|Pork liver||0.3||100% MK-4|
|Rabbit leg||0.1||100% MK-4|
|Skimmed milk yogurt||0.1||100% MK-8|
Prawns, herring, kale, spinach, broccoli, green peas, bananas, apples, oranges, margarine, corn oil, sunflower oil, olive oil, rye bread, wheat bread, sourdough bread, and tea contain vitamin K1 but not vitamin K2. Skimmed milk and coffee do not contain any vitamin K.
Recent studies found a clear association between long-term oral (or intravenous) anticoagulant treatment (OAC) and reduced bone quality due to reduction of active osteocalcin. OAC might lead to an increased incidence of fractures, reduced bone mineral density or content, osteopenia, and increased serum levels of undercarboxylated osteocalcin.
Furthermore, OAC is often linked to undesired soft-tissue calcification in both children and adults. This process has been shown to be dependent upon the action of K vitamins. Vitamin K deficiency results in undercarboxylation of MGP. Vascular calcification was shown to appear in warfarin-treated experimental animals within two weeks. Also in humans on OAC treatment, two-fold more arterial calcification was found as compared to patients not receiving vitamin K antagonists. Among consequences of anticoagulant treatment: increased aortic wall stiffness, coronary insufficiency, ischemia, and even heart failure. Arterial calcification might also contribute to systolic hypertension and ventricular hypertrophy. Coumarins, by interfering with vitamin K metabolism, are thought by some[who?] to lead to excessive calcification of cartilage and the tracheobronchial arteries.
Anticoagulant therapy is usually instituted to avoid life-threatening diseases, and high vitamin K intake interferes with anticoagulant effects. Patients on warfarin (Coumadin) or being treated with other vitamin K antagonists are therefore advised not to consume diets rich in K vitamins. However, the latest research[clarification needed] proposes to combine vitamins K with OAC to stabilize the International normalized ratio (INR, a laboratory test measure of blood coagulation).
Individuals taking anticoagulant medications, such as warfarin (coumarins), should consult their doctor before taking vitamin K2.
Text under construction
- Vermeer, C.; Braam, L. (2001). “Role of K vitamins in the regulation of tissue calcification”. Journal of Bone and Mineral Metabolism. 19 (4): 201–206. doi:10.1007/s007740170021. PMID 11448011.
- Suttie, J. W. (1995). “The importance of menaquinones in human nutrition”. Annual Review of Nutrition. 15: 399–417. doi:10.1146/annurev.nu.15.070195.002151. PMID 8527227.
- Weber, P. (2001). “Vitamin K and bone health”. Nutrition. 17 (10): 880–887. doi:10.1016/S0899-9007(01)00709-2. PMID 11684396.
- Iwamoto, I.; Kosha, S.; Noguchi, S. (1999). “A longitudinal study of the effect of vitamin K2 on bone mineral density in postmenopausal women a comparative study with vitamin D3 and estrogen-progestin therapy”. Maturitas. 31 (2): 161–164. doi:10.1016/S0378-5122(98)00114-5. PMID 10227010.
- Shearer, M. J. (2003). Physiology. Elsevier Sciences. pp. 6039–6045.
- Shearer, Martin J.; Newman, Paul (2008). “Metabolism and cell biology of vitamin K”. Thrombosis and Haemostasis. 100 (4): 530–547. doi:10.1160/th08-03-0147. ISSN 0340-6245.
- Okano, Toshio; Shimomura, Yuka; Yamane, Makiko; Suhara, Yoshitomo; Kamao, Maya; Sugiura, Makiko; Nakagawa, Kimie (25 April 2008). “Conversion of Phylloquinone (Vitamin K1) into Menaquinone-4 (Vitamin K2) in Mice”. Journal of Biological Chemistry. 283 (17): 11270–11279. doi:10.1074/jbc.M702971200. Retrieved 9 February 2019.
It is postulated that phylloquinone is converted into menaquinone-4 and accumulates in extrahepatic tissues. To clarify this, phylloquinone with a deuterium-labeled 2-methyl-1,4-naphthoquinone ring was given orally to mice, and cerebra were collected for D NMR and liquid chromatography-tandem mass spectrometry analyses.
- Booth, S. L.; Suttie, J. W. (1998). “Dietary intake and adequacy of K vitamins”. J. Nutr. 128 (5): 785–788.
- Schurgers, L. J.; Vermeer, C. (2002). “Differential lipoprotein transport pathways of K-vitamins in healthy subjects”. Biochim. Biophys. Acta. 1570 (1): 27–32. doi:10.1016/s0304-4165(02)00147-2. PMID 11960685.
- Hofbauer, L. C.; Brueck, C. C.; Shanahan, C. M.; Schoppet, M.; Dobnig, H. (2007). “Vascular calcification and osteoporosis – from clinical observation towards molecular understanding”. Osteoporos. Int. 18 (3): 251–259. doi:10.1007/s00198-006-0282-z. PMID 17151836.
- Plantalech, L.; Guillaumont, M.; Vergnaud, P.; Leclercq, M.; Delmas, P. D. (1991). “Impairment of gamma-carboxylation of circulating osteocalcin (bone Gla protein) in elderly women”. J. Bone Miner. Res. 6 (11): 1211–1216. doi:10.1002/jbmr.5650061111. PMID 1666807.
- Pucaj, K.; Rasmussen, H.; Møller, M.; Preston, T. (2011). “Safety and toxicological evaluation of a synthetic vitamin K2, menaquinone-7″. Toxicol. Mech. Methods. 21 (7): 520–532. doi:10.3109/15376516.2011.568983. PMC 3172146. PMID 21781006.
- Elder, S. J.; Haytowitz, D. B.; Howe, J.; Peterson, J. W.; Booth, S. L. (2006). “Vitamin K contents of meat, dairy, and fast food in the U.S. Diet”. J. Agric. Food Chem. 54 (2): 463–467. doi:10.1021/jf052400h. PMID 16417305.
- Schurgers, Leon J.; Vermeer, Cees (November 2000). “Determination of phylloquinone and menaquinones in food. Effect of food matrix on circulating vitamin K concentrations”. Haemostasis. 30 (6): 298–307. doi:10.1159/000054147. PMID 11356998. Retrieved 12 October 2016.
- Tsukamoto, Y.; Ichise, H.; Kakuda, H.; Yamaguchi, M. (2000). “Intake of fermented soybean (natto) increases circulating vitamin K2 (menaquinone-7) and gamma-carboxylated osteocalcin concentration in normal individuals”. J. Bone Miner. Metab. 18 (4): 216–222. doi:10.1007/s007740070023. PMID 10874601.
- Kaneki, M.; Hodges, S. J.; Hosoi, T.; Fujiwara, S.; Lyons, A.; Crean, S. J.; Ishida, N.; Nakagawa, M.; Takechi, M.; Sano, Y.; Mizuno, Y.; Hoshino, S.; Miyao, M.; Inoue, S.; Horiki, K.; Shiraki, M.; Ouchi, Y.; Orimo, H. (2001). “Japanese fermented soybean food as the major determinant of the large geographic difference in circulating levels of K vitamins. 2: possible implications for hip-fracture risk”. Nutrition. 17 (4): 315–321. doi:10.1016/s0899-9007(00)00554-2.
- “On the Trail of the Elusive X-Factor: Vitamin K2 Revealed”.
- “Hook Line and Stinker” (PDF).
- Rhéaume-Bleue, Kate (August 27, 2013). Vitamin K2 and the Calcium Paradox: How a Little-Known Vitamin Could Save Your Life. Harper. pp. 66–67. ISBN 978-0062320049.
- Caraballo, P.J.; Gabriel, S.E.; Castro, M.R.; Atkinson, E.J.; Melton, L.J., III (1999). “Changes in bone density after exposure to oral anticoagulants: a meta-analysis”. Osteoporos. Int. 9 (5): 441–448. doi:10.1007/s001980050169.
- Barnes, C.; Newall, F.; Ignjatovic, V.; Wong, P.; Cameron, F.; Jones, G.; P., Monagle (2005). “Reduced bone density in children on long-term warfarin”. Pediatr. Res. 57 (4): 578–581. doi:10.1203/01.pdr.0000155943.07244.04. PMID 15695604.
- Hawkins, D.; Evans, J. (2005). “Minimising the risk of heparin-induced osteoporosis during pregnancy”. Expert Opin. Drug Saf. 4 (3): 583–590. doi:10.1517/147403126.96.36.1993. PMID 15934862.
- Price, P. A.; Faus, S. A.; Williamson, M. K. (1998). “Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves”. Arterioscler. Thromb. Vasc. Biol. 18 (9): 1400–1407. doi:10.1161/01.atv.18.9.1400.
- Schurgers, L. J.; Aebert, H.; Vermeer, C.; Bültmann, B.; Janzen, J. (2004). “Oral anticoagulant treatment: friend or foe in cardiovascular disease?”. Blood. 104 (10): 3231–3232. doi:10.1182/blood-2004-04-1277. PMID 15265793.
- Koos, R.; Mahnken, A. H.; Mühlenbruch, G.; Brandenburg, V.; Pflueger, B.; Wildberger, J. E.; Kühl, H. P. (2005). “Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography”. Am. J. Cardiol. 96 (6): 747–749. doi:10.1016/j.amjcard.2005.05.014. PMID 16169351.
- Zieman, S. J.; Melenovsky, V.; Kass, D. A. (2005). “Mechanisms, pathophysiology, and therapy of arterial stiffness”. Arterioscler. Thromb. Vasc. Biol. 25 (5): 932–943. doi:10.1161/01.atv.0000160548.78317.29. PMID 15731494.
- Raggi, P.; Shaw, L. J.; Berman, D. S.; Callister, T. Q. (2004). “Prognostic value of coronary artery calcium screening in subjects with and without diabetes”. J. Am. Coll. Cardiol. 43 (9): 1663–1669. doi:10.1016/j.jacc.2003.09.068. PMID 15120828.